First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

Abstract This study aimed to identify a recommended phase II dose and evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary clinical activity of JNJ‐63709178, a CD123/CD3 dual‐targeting antibody, in patients with relapsed or refractory acute myeloid leukemia. Intraven...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Michael Boyiadzis, Pinkal Desai, Nikki Daskalakis, William Donnellan, Lucille Ferrante, Jenna D. Goldberg, Michael R. Grunwald, Christina Guttke, Xiang Li, Jose Antonio Perez‐Simon, Olga Salamero, Trevor Tucker, Xiaoying Xu, Jay Yang, Naveen Pemmaraju, Juan Manuel Alonso‐Dominguez
Μορφή: Άρθρο
Γλώσσα:English
Έκδοση: Wiley 2023-03-01
Σειρά:Clinical and Translational Science
Διαθέσιμο Online:https://doi.org/10.1111/cts.13467

Διαδίκτυο

https://doi.org/10.1111/cts.13467

Παρόμοια τεκμήρια